

DAFTAR PUSTAKA

1. Gupta B, Johnson NW, Kumar N. Global Epidemiology of Head and Neck Cancers: A Continuing Challenge. *Oncology*. 2016;91(1):13–23.
2. Bray F, Ferlay J, Soerjomataram I. Global Cancer Statistics 2018 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2018;0:1–31.
3. World Health Organization. Estimated age-standardized incidence rates (World) in 2018 [Internet]. GLOBOCAN. 2018 [cited 2019 Feb 11]. Available from: <https://gco.iarc.fr/today/home>
4. Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. *Mayo Clin Proc*. 2016;91(3):386–96.
5. McDermott JD, Bowles DW. Epidemiology of Head and Neck Squamous Cell Carcinomas: Impact on Staging and Prevention Strategies. *Curr Treat Options Oncol*. 2019;20(5):1–13.
6. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. *J Clin Oncol*. 2015;33(29):3235–42.
7. Kazuhiro Kobayashi, Hisamatsu K, Suzui N, Hara A. A Review of HPV-Related Head and Neck Cancer. *J Clin Med*. 2018;7(241):1–11.
8. Meng H, Miao S, Chen K, Li H, Yao G. Association of p16 as prognostic factors for Oropharyngeal cancer : Evaluation of p16 in 1470 Patients for a 16 years study in northeast china. *Biomed Res Int*. 2018;2018:1–9.
9. Spence T, Bruce J, Yip KW, Liu FF. HPV associated head and neck cancer. *Cancers (Basel)*. 2016;8(75):1–12.
10. Bryant AK, Sojourner EJ, Vitzthum LK, Zakeri K, Shen H, Murphy JD, et al. Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer. *J Natl Cancer Inst*. 2018;110:1393–9.
11. Silva SD, Nonogaki S, Soares FA, Kowalski LP, Silva SD, Nonogaki S, et al. p16 (INK4a) has clinicopathological and prognostic impact on oropharynx and larynx squamous cell carcinoma p16 (INK4a) has clinicopathological and prognostic impact on oropharynx and larynx squamous cell carcinoma. *Braz J Med Biol Res*. 2012;45(12):1237–333.
12. Hsieh JCH, Wang HM, Wu MH, Chang KP, Chang PH, Liao CT, et al. Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy. *Head Neck*. 2019;41(S1):19–45.

13. Nelson EE, Guyer AE. Molecular Pathology of Head and Neck. *Annu Rev Pathol.* 2009;1:49–70.
14. Jouhi L, Hagstrom J, Atula T, Makitie A. Is p16 an adequate surrogate for human papillomavirus status determination ? *Curr Opin Otolaryngol Head Neck Surg.* 2017;25(2):108–12.
15. Smith EM, Rubenstein LM, Hoffman H, Haugen TH, Turek LP. Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer. *Infect Agents Cancer.* 2010;5(4):1–10.
16. Ralli M, Singh S, Yadav SP., Sharma N, Verma R, Rajev Sen. Assessment and clinicopathological correlation of p16 expression in head and neck squamous cell carcinoma. *J Can Res Ther.* 2016;12(1):232–7.
17. Ampur O., Sudarsa I., I.B Suryawisesa. Association of p16 expression with clinicopathological features of oral cavity squamous cell carcinoma patients in Bali. *Bali Med J.* 2016;5(3):362–6.
18. El-Naggar AK, Chan JKC, Rubin Grandis J, Takata T, Slootweg PJ. WHO classification of head and neck tumours. Lyon: IARC; 2017.
19. Cardesa A, Slootweg PJ. *Pathology of the Head and Neck.* Germany: Springer; 2006.
20. Božena Šarcevic. Specifics of Histopathological Analysis of Head and Neck Cancer. *Lib Oncol.* 2016;44(2–3):31–5.
21. Roh J, Muelleman T, Tawfik O, Thomas SM. Perineural Growth in Head and Neck Squamous Cell Carcinoma: A Review. *Oral Oncol.* 2016;51(1):16–23.
22. Jimenez L, Jayakar SK, Ow TJ, Segall JE. Mechanisms of invasion in head and neck cancer. *Arch Pathol Lab Med.* 2015;139(11):1334–48.
23. Frunza A, Slavescu D, Lascar I. Perineural invasion in head and neck cancers - a review-. *J Med Life.* 2014;7(2):121–3.
24. Huyett P, Gilbert M, Liu L, Ferris RL, Kim S. A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma. *J Vis Exp.* 2017;119(January):1–10.
25. Mesolella M, Iorio B, Misso G, Luce A, Cimmino M, Iengo M, et al. Role of perineural invasion as a prognostic factor in laryngeal cancer. *Oncol Lett.* 2016;11:2595–8.
26. Chen S, Zhang B, Zhou B, Zhu C, Sun L, Feng Y. Perineural invasion of cancer: a complex crosstalk between cells and molecules in the perineural niche. *Am J Cancer Res.* 2019;9(1):1–21.
27. Romagosa C, Simonetti S, López-Vicente L, Mazo A, Lleonart ME, Castellvi J, et al. P16Ink4a overexpression in cancer: A tumor suppressor

- gene associated with senescence and high-grade tumors. *Oncogene*. 2011;30(18):2087–97.
28. Jung A, Schrauder M, Oswald U, Knoll C, Sellberg P, Palmqvist R, et al. The Invasion Front of Human Colorectal Adenocarcinomas Shows Co-Localization of Nuclear β -Catenin, Cyclin D1, and p16INK4A and Is a Region of Low Proliferation. *AJP*. 2001;159(5):1613–7.
 29. Dok R, Glorieux M, Holacka K, Bamps M, Nuyts S. Dual role for p16 in the metastasis process of HPV positive head and neck cancers. *Mol Cancer*. 2017;16(113):1–6.
 30. Rothenberg SM, Ellisen LW. The molecular pathogenesis of head and neck squamous cell carcinoma. *J Clin Invest*. 2012;122(6):1951–7.
 31. Stadler M, Patel M, Couch M, Hayes DN. Molecular Biology of Head & Neck Cancer: Risks and Pathways. *Hematol Oncol Clin North Am*. 2008;22(6):1099–124.
 32. Cohen N, Fedewa S. Epidemiology and Demographics of the Head and Neck Cancer Population. *Oral Maxillofac Surg Clin NA*. 2018;30(4):381–95.
 33. James Byron, Wackym PA, Ballenger JJ. Ballenger's otorhinolaryngology : head and neck surgery. 17th ed. Connecticut: People's Medical Pub. House/B C Decker; 2009. 1209 p.
 34. Brennan JA, Boyle JO, M.Koch W, Goodman SN, Hruban RH, Eby YJ, et al. Association Between Cigarette Smoking and Mutation of the p53 Gene in Squamous Cell Carcinoma of the Head and Neck. *N Engl J Med*. 2001;344(15):1125–31.
 35. Rettig EM, D'Souza G. Epidemiology of Head and Neck Cancer. *Surg Oncol Clin N Am*. 2015;24(3):379–96.
 36. Kawakita D, Matsuo K. Alcohol and head and neck cancer. *Cancer Metastasis Rev*. 2017;36(3):425–34.
 37. Infodatin KEMENKES RI. Perilaku Merokok Masyarakat Indonesia. Jakarta: Infodatin KEMENKES RI; 2013. 1-12 p.
 38. Chen Y, Chang JT, Liao C, Wang H, Yen T, Chiu C, et al. Head and neck cancer in the betel quid chewing area : recent advances in molecular carcinogenesis. *Cancer Sci*. 2008;99(8):1507–14.
 39. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: Its role in pathogenesis and clinical implications. *Clin Cancer Res*. 2009;15(22):6758–62.
 40. Stanley MA. Epithelial cell responses to infection with human papillomavirus. *Clin Microbiol Rev*. 2012;25(2):215–22.

41. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review. *Cancer Epidemiol Biomarkers Prev.* 2005;14(February):467–75.
42. Leemans CR, Braakhuis BJM, Brakenhoff RH. The molecular biology of head and neck cancer. *Nat Rev Cancer.* 2011;11(1):9–22.
43. Gillison ML, Broutian T, Pickard RKL, Tong ZY, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009–2010. *JAMA - J Am Med Assoc.* 2012;307(7):693–703.
44. Park JE, Seo JE, Lee JY, Kwon H. Distribution of Seven N-Nitrosamines in Food. *Toxicol Res.* 2015;31(3):279–88.
45. Hopkins J, Cescon DW, Tse D, Bradbury P, Xu W, Ma C, et al. Minireview Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review. 2008;17(March):490–500.
46. Kutler DI, Auerbach AD, Satagopan J, Giampietro PF, Batish SD, Huvos AG, et al. High Incidence of Head and Neck Squamous Cell Carcinoma in Patients With Fanconi Anemia. *Arch Otolaringol Head Neck Surg.* 2003;129:106–12.
47. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. *Lancet.* 2007;370(9581):59–67.
48. Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: A nationwide cohort study in Sweden. *Br J Cancer.* 2003;89(7):1221–7.
49. Kumar V, K. Abbas A, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 9th editio. Philadelphia: Elsevier Masson SAS; 2015. 727-41 p.
50. Dok R, Nuyts S. HPV positive head and neck cancers: Molecular pathogenesis and evolving treatment strategies. *Cancers (Basel).* 2016;8(4):1–16.
51. Mooren JJ, Gültekin SE, Straetmans MJAA, Haesevoets A, Peutz-Kootstra CJ, Huebbers CU, et al. P16INK4Aimmunostaining is a strong indicator for high-risk-HPV-associated oropharyngeal carcinomas and dysplasias, but is unreliable to predict low-risk-HPV-infection in head and neck papillomas and laryngeal dysplasias. *Int J Cancer.* 2014;134(9):2108–17.
52. Wang H, Sun R, Lin H, Hu W. P16INK4A as a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: Consideration of some aspects. *Cancer Sci |.* 2013;104(12):1553–9.

53. Quelle DE, Ashmun RA, Hannon GJ, Rehberger PA, Trono D, Richter KH, et al. Cloning and characterization of murine p16INK4a and p15INK4b genes. *Oncogene*. 1995 Aug 17;11(4):635–45.
54. Sritippho T, Chotjumlom P, Iamaroon A. Roles of Human Papillomaviruses and p16 in Oral Cancer. *Asian Pacific J Cancer Prev*. 2015;16:6193–200.
55. El-naggar AK, Westra WH. P16 Expression as A Surrogate Marker for HPV-Related Oropharyngeal Carcinoma: A Guide for Interpretative Relevance and Consistency. *Head Neck*. 2012;(April):459–61.
56. Lester Thompson., Goldblum J. *Head and Neck Pathology*. second edi. Philadelphia: Elsevier Saunders; 2015. 155 p.
57. Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in oropharyngeal cancer: the basics to know in clinical practice. *Acta Otorhinolaryngol Ital*. 2014;34(5):299–309.
58. Datar UV, Kale A, Mane D. Oral Carcinoma Cuniculatum: A New Entity in the Clinicopathological Spectrum of Oral Squamous Cell Carcinoma. *J Clin Diagnostic Res*. 2017;11(1):37–9.
59. Gu X, Jiang R, Fowler MR. Acantholytic Squamous Cell Carcinoma in Upper Aerodigestive Tract: Histopathology, Immunohistochemical Profile and Epithelial Mesenchymal Transition Phenotype Change. *Head Neck Pathol*. 2012;6(4):438–44.
60. Donthi D, Ramaswamy AS, Mahalingasetti PB. Acantholytic squamous cell carcinoma of the tongue: A diagnostic challenge. *Clin Cancer Investig J*. 2014;3(2):179–81.
61. Zhang Z, Liu R, Jin R, Fan Y, Li T, Shuai Y. Integrating Clinical and Genetic Analysis of Perineural Invasion in Head and Neck Squamous Cell Carcinoma. *Front Oncol*. 2019;9(May):1–15.
62. Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: A review of the literature. *Cancer*. 2009;115(15):3379–91.
63. Laske RD, Scholz I, Ikenberg K, Meerwein C, Vital DG, Studer G, et al. Perineural Invasion in Squamous Cell Carcinoma of the Oral Cavity: Histology, Tumor Stage, and Outcome. *Laryngoscope*. 2016;1(February):13–8.
64. Fagan JJ, Collins B, Barnes L, Amico FD, Myers EN, Johnson JT. Perineural Invasion in Squamous Cell Carcinoma of the Head and Neck. *Arch Otolaryngol Head Neck Surg*. 1998;124(June):637–40.
65. Grégoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010;21(SUPPL. 5):184–6.

66. NCCN Guideline Members. NCCN Clinical Practice Guidelines in Oncology, Head and Neck Cancers [Internet]. National Comprehensive Cancer Network (Inc). 2018. Available from: <https://www.nccn.org>
67. Hay A, Ganly I. Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for Therapy. *Rare cancers Ther.* 2015;3(1):89–117.
68. Rieke DT, Keilholz U. Targeted Therapy of Head and Neck Cancer. *Oncol Res Treat.* 2016;39:780–6.
69. Lou Y, Diao L, Cuentas ERP, Denning WL, Chen L, Fan Y, et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. *Clin Cancer Res.* 2016;22(14):3630–42.
70. Dahlan MS. Besar Sampel dalam Penelitian Kedokteran dan Kesehatan. seri 2. Jakarta: Arkans; 2006. 15-30 p.
71. Golusinski W, Rene Leemans. HPV Infection in Head and Neck Cancer. Golusiński W, Leemans CR, Dietz A, editors. Cham: Springer International Publishing; 2017. 150-151 p. (Recent Results in Cancer Research; vol. 206).
72. Will Z, Ilan C. Equivocal p16 Immunostaining in Squamous Cell Carcinoma of the Head and Neck : Staining Patterns are Suggestive of HPV Status. *Head Neck Pathol.* 2012;6:422–9.
73. Abclonal. Immunohistochemistry Protocol (Paraffin) [Internet]. 2014. Available from: https://abclonal.com/Uploads/protocol/IHC-P_protocol.pdf
74. Ayuni L. Profil Penderita Karsinoma Sel Skuamosa Kepala dan Leher (KSSKL) di RSUP Haji Adam Malik Tahun 2012-2016. *Repos USU.* 2017;35.
75. Chadha P, Bhushan R, Farhana Siddiqui. Original article : Demographic & clinicopathological profile of head & neck squamous cell carcinomas : an Indian insight. *Indian J Basic Appl Med Res.* 2016;5(4):535–41.
76. Anisimov VN. Biology of aging and cancer. *Cancer Control.* 2007;14(1):23–31.
77. Van Monsjou HS, Wreesmann VB, Van Den Brekel MWM, Balm AJM. Head and neck squamous cell carcinoma in young patients. *Oral Oncol.* 2013;49(12):1097–102.
78. Syah M, Permana AD, Soeseno B. Epidemiologi Penderita Tumor Ganas Kepala Leher di Departemen Telinga Hidung Tenggorokan Kepala Leher Rumah Sakit Dr. Hasan Sadikin Bandung Indonesia Periode 2010 – 2014. *Tunas Med J Kedokt dan Kesehat.* 2016;3(1):57–62.

79. Lopez AD, Collishaw NE, Piha T. A Descriptive Model of the Cigarette Epidemic in Developed Countries on JSTOR. *Tob Control*. 1994;3(3):242–7.
80. Dahlstrom KR, Little JA, Zafereo ME, Lung M, Wei Q, Sturgis EM. Squamous Cell Carcinoma of The Head and Neck in Never Smoker-Never Drinkers: A Descriptive Epidemiologic Study. *Head Neck*. 2008;30(January):75–84.
81. Mehanna H, Paleri V, West CML, Nutting C. Head and neck cancer-Part 1: Epidemiology, presentation, and preservation. *Clin Otolaryngol*. 2011;36(1):65–8.
82. Mendelsohn AH, Lai CK, Shintaku IP, Elashoff DA, Dubinett SM, Abemayor E, et al. Histopathologic Findings of HPV and p16 Positive HNSCC. *Laryngoscope*. 2010;120(September):1788–94.
83. Institue NC. SEER Cancer Stat Facts [Internet]. 2018 [cited 2020 Feb 3]. Available from: <https://seer.cancer.gov/statfacts/>
84. Joshi P, Dutta S, Chaturvedi P, Nair S. Head and Neck Cancers in Developing Countries. *Rambam Maimonides Med J*. 2014 Apr 28;5(2):1–6.
85. José M, Galbiatti AL, Maria L, Marucci GH, Russo A, Torreglosa M, et al. Clinical and epidemiological characteristics of patients in the head and neck surgery department of a university hospital. *Sao Paulo Med J*. 2012;130(5):307–13.
86. Worsham MJ. Identifying the risk factors for late-stage head and neck cancer. *Expert Rev Anticancer Ther*. 2011 Sep 10;11(9):1321–5.
87. Huang SH, O’Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. *Curr Treat Options Oncol*. 2017;18(7):1–13.
88. Bhargava A, Saigal S, Chalishazar M. Systems In Oral Squamous Cell Carcinoma : A Review. *J Int Oral Heal*. 2010;2(4):1–10.
89. Padma R, Kalaivani A, Sundaresan S, Sathish P. The relationship between histological differentiation and disease recurrence of primary oral squamous cell carcinoma. *J Oral Maxillofac Pathol*. 2017 Sep 1;21(3):461.
90. Zhu J, Zhou R, Wang Y, Yu M. Perineural invasion as a prognostic factor in head and neck squamous cell carcinoma: a systematic review and meta-analysis. *Acta Otolaryngol*. 2019;139(11):1038–43.
91. Brown IS. Pathology of Perineural Spread. *J Neurol Surgery, Part B Skull Base*. 2016;77(2):124–30.
92. Jr JSL, Beadle B, Bishop JA, Chernock RD, Colasacco C, Ascp SCT, et al. Human Papillomavirus Testing in Head and Neck. *Arch Pathol Lab Med*. 2018;142:559–97.

93. Albers AE, Qian X, Andreas MK, Coordes A. Meta analysis : HPV and p16 pattern determines survival in patients with HNSCC and identifies potential new biologic subtype. *Nature*. 2017;6(November):1–14.
94. Vukelic J, Dobrila-Dintinjana R, Dekanic A, Marijic B, Cubranic A, Braut T. The Relevance of Assessing the Cell Proliferation Factor Ki-67 in Squamous Cell Carcinoma of the Larynx. *Biomed Res Int*. 2019 Jan 15;2019:1–6.
95. Muirhead DM, Hoffman HT, Robinson RA. Correlation of clinicopathological features with immunohistochemical expression of cell cycle regulatory proteins p16 and retinoblastoma: Distinct association with keratinisation and differentiation in oral cavity squamous cell carcinoma. *J Clin Pathol*. 2006;59(7):711–5.
96. Husain N, Neyaz A. *Journal of Oral Biology and Craniofacial Research* Human papillomavirus associated head and neck squamous cell carcinoma : Controversies and new concepts. *J Oral Biol Craniofacial Res*. 2017;7(3):198–205.
97. Ragomir LPD, Imionescu CRS, Ritescu CLMĂRGĂ. P53, p16 dan Ki67 immunoexpression in oral squamous carcinoma. *Rom J Morphol Embriol*. 2012;53(1):89–93.
98. Yuen PW, Man M, Lam KY, Kwong YL. Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. *J Clin Pathol*. 2002;55(1):58–60.
99. Fåhræus R, Lane DP. The p16 INK4a tumour suppressor protein inhibits α v β 3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of α v β 3 to focal contacts. *EMBO J*. 1999;18(8):2106–18.
100. Cho YA, Chung JM, Ryu H, Kim EK, Cho BC, Yoon SO. Investigating Trk Protein Expression between Oropharyngeal and Non-oropharyngeal Squamous Cell Carcinoma: Clinical implications and possible roles of human papillomavirus infection. *Cancer Res Treat*. 2019;51(3):1052–63.
101. Bapat AA, Munoz RM, Von Hoff DD, Han H. Blocking nerve growth factor signaling reduces the neural invasion potential of pancreatic cancer cells. *PLoS One*. 2016;October:1–15.